Cargando…
Deciphering the vedolizumab dosing conundrum in IBD: when less is more
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279744/ https://www.ncbi.nlm.nih.gov/pubmed/34497148 http://dx.doi.org/10.1136/gutjnl-2021-325893 |
| _version_ | 1784746468133830656 |
|---|---|
| author | Adolph, Timon Erik Siegmund, Britta |
| author_facet | Adolph, Timon Erik Siegmund, Britta |
| author_sort | Adolph, Timon Erik |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9279744 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92797442022-08-01 Deciphering the vedolizumab dosing conundrum in IBD: when less is more Adolph, Timon Erik Siegmund, Britta Gut Commentary BMJ Publishing Group 2022-08 2021-09-08 /pmc/articles/PMC9279744/ /pubmed/34497148 http://dx.doi.org/10.1136/gutjnl-2021-325893 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Commentary Adolph, Timon Erik Siegmund, Britta Deciphering the vedolizumab dosing conundrum in IBD: when less is more |
| title | Deciphering the vedolizumab dosing conundrum in IBD: when less is more |
| title_full | Deciphering the vedolizumab dosing conundrum in IBD: when less is more |
| title_fullStr | Deciphering the vedolizumab dosing conundrum in IBD: when less is more |
| title_full_unstemmed | Deciphering the vedolizumab dosing conundrum in IBD: when less is more |
| title_short | Deciphering the vedolizumab dosing conundrum in IBD: when less is more |
| title_sort | deciphering the vedolizumab dosing conundrum in ibd: when less is more |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279744/ https://www.ncbi.nlm.nih.gov/pubmed/34497148 http://dx.doi.org/10.1136/gutjnl-2021-325893 |
| work_keys_str_mv | AT adolphtimonerik decipheringthevedolizumabdosingconundruminibdwhenlessismore AT siegmundbritta decipheringthevedolizumabdosingconundruminibdwhenlessismore |